12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MultiStem: Phase II ongoing

Athersys said an independent safety committee recommended continuation to the high dose of MultiStem in a double-blind, placebo-controlled, U.S. Phase II trial based on a review of safety data. The trial is evaluating single doses of IV MultiStem given 24-36 hours following a stroke in about 140 patients. MultiStem has Orphan Drug designation...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >